Molecular pathogenesis of Waldenström's macroglobulinemia

Haematologica

Volumn 97, Issue 9, 2012, Pages 1281-1290

  Braggio, Esteban ^a   Philipsborn, Casey ^b   Novak, Anne ^c   Hodge, Lucy ^c   Ansell, Stephen ^c   Fonseca, Rafael ^a  

^a MAYO CLINIC   (United States)

^b MIDWESTERN UNIVERSITY   (United States)

^c MAYO CLINIC   (United States)

Author keywords

aCGH; IL 6; Jak STAT; PI3K Akt; WM, NF kB signaling pathway

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL) IMIDAZO [4, 5 C] QUINOLIN 2 (1H, 3H) ONE; 1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; BORTEZOMIB; CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CYCLIN DEPENDENT KINASE; DEXAMETHASONE; EVEROLIMUS; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE; IMMUNOGLOBULIN M; INTERLEUKIN 6; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA 155; MICRORNA 15A; MICRORNA 16; MICRORNA 9; MYELOID DIFFERENTIATION FACTOR 88; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; RAB PROTEIN; RAPAMYCIN; RHO FACTOR; RITUXIMAB; STAT PROTEIN; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CELL INTERACTION; CHROMOSOME DELETION; CHROMOSOME LOSS; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; CYTOGENETICS; DNA SEQUENCE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC SCREENING; HUMAN; IMMUNOFLOURESCENCE TEST; IMMUNOPHENOTYPING; INFLAMMATION; LYMPHOCYTIC INFILTRATION; POLYMERASE CHAIN REACTION; PROTEOME; REVIEW; SIGNAL TRANSDUCTION; WALDENSTROEM MACROGLOBULINEMIA; PATHOLOGY;

HUMANS; WALDENSTROM MACROGLOBULINEMIA;

EID: 84865842212     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.068478     Document Type: Review

References (89)

1. Gertz MA, Fonseca R, Rajkumar SV. Waldenstrom's macroglobulinemia. Oncologist. 2000;5(1):63-7.
2. Ghobrial IM, Gertz MA, Fonseca R. Waldenstrom macroglobulinaemia. Lancet Oncol. 2003;4(11):679-85.
3. Ansell SM, Kyle RA, Reeder CB, Fonseca R, Mikhael JR, Morice WG, et al. Diagnosis and management of Waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc. 2010;85(9):824-33.
4. Ghobrial IM, Fonseca R, Gertz MA, Plevak MF, Larson DR, Therneau TM, et al. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol. 2006; 133(2):158-64.
5. Ansell SM, Kyle RA, Reeder CB, Fonseca R, Mikhael JR, Morice WG, et al. Diagnosis and management of Waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc. 2010;85(9):824-33.
6. Itzykson R, Le Garff-Tavernier M, Katsahian S, Diemert MC, Musset L, Leblond V. Serum-free light chain elevation is associated with a shorter time to treatment in Waldenstrom's macroglobulinemia. Haematologica. 2008;93(5):793-4.
7. Leleu X, Moreau AS, Weller E, Roccaro AM, Coiteux V, Manning R, et al. Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. Leuk Lymphoma. 2008;49(6):1104-7.
8. Leleu X, Koulieris E, Maltezas D, Itzykson R, Xie W, Manier S, et al. Novel M-component based biomarkers in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011;11(1):164-7.
9. Hivert B, Caron C, Petit S, Charpy C, Fankam-Siaka C, Duhamel A, et al. Clinical and Prognostic Implications of Low or High Level of Von Willebrand Factor (VWF) In Waldenström Macroglobulinemia (WM) Patients (pts). A Clinicopathological Study on 72 Pts. Blood (ASH Annual Meeting Abstracts). 2010;116:Abstract 2438.
10. Morel P, Monconduit M, Jacomy D, Lenain P, Grosbois B, Bateli C, et al. Prognostic factors in Waldenstrom macroglobulinemia: A report on 232 patients with the description of a new scoring system and its validation on 253 other patients. Blood. 2000;96 (3):852-8.
11. Dimopoulos M, Gika D, Zervas K, Kyrtsonis M, Symeonidis A, Anagno-stopoulos A, et al. The international staging system for multiple myeloma is applicable in symptomatic Waldenstrom's macroglobulinemia. Leuk Lymphoma. 2004;45(9): 1809-13.
12. Morel P, Duhamel A, Gobbi P, Dimopoulos MA, Dhodapkar MV, McCoy J, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009;113(18):4163-70.
13. Leleu X, Soumerai J, Roccaro A, Hatjiharissi E, Hunter ZR, Manning R, et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs. J Clin Oncol. 2009;27(2):250-5.
14. Aoki H, Takishita M, Kosaka M, Saito S. Frequent somatic mutations in D and/or JH segments of Ig gene in Waldenstrom's macroglobulinemia and chronic lymphocytic leukemia (CLL) with Richter's syndrome but not in common CLL. Blood. 1995;85(7):1913-9.
15. Wagner SD, Martinelli V, Luzzatto L. Similar patterns of V kappa gene usage but different degrees of somatic mutation in hairy cell leukemia, prolymphocytic leukemia, Waldenstrom's macroglobulinemia, and myeloma. Blood. 1994;83(12): 3647-53.
16. Martin-Jimenez P, Garcia-Sanz R, Balan-zategui A, Alcoceba M, Ocio E, Sanchez ML, et al. Molecular characterization of heavy chain immunoglobulin gene rearrangements in Waldenstrom's macro-globulinemia and IgM monoclonal gammopathy of undetermined significance. Haematologica. 2007;92(5):635-42.
17. Kriangkum J, Taylor BJ, Mant MJ, Treon SP, Belch AR, Pilarski LM. The malignant clone in Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30(2):132-5.
18. Kriangkum J, Taylor BJ, Treon SP, Mant MJ, Belch AR, Pilarski LM. Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual Bcell origin and an expansion of polyclonal B cells in peripheral blood. Blood. 2004;104 (7):2134-42.
19. Sahota SS, Forconi F, Ottensmeier CH, Stevenson FK. Origins of the malignant clone in typical Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30(2):136-41.
20. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346(8):564-9.
21. McMaster ML, Goldin LR, Bai Y, Ter-Minassian M, Boehringer S, Giambarresi TR, et al. Genomewide linkage screen for Waldenstrom macroglobulinemia susceptibility loci in high-risk families. Am J Hum Genet. 2006;79(4):695-701.
22. Kyle RA, Therneau TM, Rajkumar SV, Remstein ED, Offord JR, Larson DR, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood. 2003;102(10):3759-64.
23. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Semin Oncol. 2003;30(2):169-71.
24. Kristinsson SY, Fears TR, Gridley G, Turesson I, Mellqvist UH, Bjorkholm M, et al. Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood. 2008;112(9): 3582-6.
25. Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S, et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood. 2007;109(8):3177-88.
26. Treon SP, Hunter ZR, Aggarwal A, Ewen EP, Masota S, Lee C, et al. Characterization of familial Waldenstrom's macroglobulinemia. Ann Oncol. 2006;17(3):488-94.
27. McMaster ML. Familial Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30 (2):146-52.
28. Royer RH, Koshiol J, Giambarresi TR, Vasquez LG, Pfeiffer RM, McMaster ML. Differential characteristics of Waldenstrom macroglobulinemia according to patterns of familial aggregation. Blood. 2010;115(22): 4464-71.
29. Goldin LR, Landgren O. Autoimmunity and lymphomagenesis. Int J Cancer. 2009;124(7):1497-502.
30. Grass S, Preuss KD, Wikowicz A, Terpos E, Ziepert M, Nikolaus D, et al. Hyper-phosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemia. Blood. 2011;117(10): 2918-23.
31. Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003;30(2):110-5.
32. Schop RF, Kuehl WM, Van Wier SA, Ahmann GJ, Price-Troska T, Bailey RJ, et al. Waldenstrom macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood. 2002;100(8):2996-3001.
33. Mansoor A, Medeiros LJ, Weber DM, Alexanian R, Hayes K, Jones D, et al. Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia. Chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course. Am J Clin Pathol. 2001;116(4):543-9.
34. San Miguel JF, Vidriales MB, Ocio E, Mateo G, Sanchez-Guijo F, Sanchez ML, et al. Immunophenotypic analysis of Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30(2):187-95.
35. Owen RG, Barrans SL, Richards SJ, O'Connor SJ, Child JA, Parapia LA, et al. Waldenstrom macroglobulinemia. Develo-pment of diagnostic criteria and identification of prognostic factors. Am J Clin Pathol. 2001;116(3):420-8.
36. Ahmann GJ, Jalal SM, Juneau AL, Christensen ER, Hanson CA, Dewald GW, et al. A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies. Cancer Genet Cytogenet. 1998;101(1):7-11.
37. Mansoor A, Medeiros LJ, Weber DM, Alexanian R, Hayes K, Jones D, et al. Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia. Chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course. Am J Clin Pathol. 2001;116(4):543-9.
38. Schop RF, Van Wier SA, Xu R, Ghobrial I, Ahmann GJ, Greipp PR, et al. 6q deletion discriminates Waldenstrom macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. Cancer Genet Cytogenet. 2006;169(2):150-3.
39. Nguyen-Khac F, Lejeune J, Chapiro E, Mould S, Barin C, Daudignon A, et al. Cytogenetic abnormalities in a cohort of 171 patients with Waldenström macroglobulinemia before treatment: clinical and biological correlations. Blood (ASH Annual Meeting Abstracts). 2010;116:Abstract 801.
40. Braggio E, Dogan A, Keats JJ, Chng WJ, Huang G, Matthews JM, et al. Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities. Mod Pathol. 2012;25(5):651-60.
41. Ferreira BI, Garcia JF, Suela J, Mollejo M, Camacho FI, Carro A, et al. Comparative genome profiling across subtypes of lowgrade B-cell lymphoma identifies type-specific and common aberrations that target genes with a role in B-cell neoplasia. Haematologica. 2008;93(5):670-9.
42. Rinaldi A, Mian M, Chigrinova E, Arcaini L, Bhagat G, Novak U, et al. Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. Blood. 2011;117(5):1595-604.
43. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910-6.
44. Chang H, Samiee S, Li D, Patterson B, Chen CI, Stewart AK. Analysis of IgH translocations, chromosome 13q14 and 17p13.1(p53) deletions by fluorescence in situ hybridization in Waldenstrom's macroglobulinemia: a single center study of 22 cases. Leukemia. 2004;18(6):1160-2.
45. Terre C, Nguyen-Khac F, Barin C, Mozziconacci MJ, Eclache V, Leonard C, et al. Trisomy 4, a new chromosomal abnormality in Waldenstrom's macroglobulinemia: a study of 39 cases. Leukemia. 2006;20(9):1634-6.
46. Braggio E, Keats JJ, Leleu X, Van Wier S, Jimenez-Zepeda VH, Valdez R, et al. Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia. Cancer Res. 2009;69 (8):3579-88.
47. Braggio E, Keats JJ, Leleu X, Wier SV, Jimenez-Zepeda VH, Schop RF, et al. Highresolution genomic analysis in Walden-strom's macroglobulinemia identifies disease-specific and common abnormalities with marginal zone lymphomas. Clin Lymphoma Myeloma. 2009;9(1):39-42.
48. Ocio EM, Schop RF, Gonzalez B, Van Wier SA, Hernandez-Rivas JM, Gutierrez NC, et al. 6q deletion in Waldenstrom macroglobulinemia is associated with features of adverse prognosis. Br J Haematol. 2007;136 (1):80-6.
49. Madan RA, Chang VT, Yook C, Baddoura FK, Srinivas S, Kasimis B. Waldenstrom's macroglobulinemia evolving into acute lymphoblastic leukemia: a case report and a review of the literature. Leukemia. 2004;18(8):1433-5.
50. Chang H, Qi X, Xu W, Reader JC, Ning Y. Analysis of 6q deletion in Waldenstrom macroglobulinemia. Eur J Haematol. 2007; 79(3):244-7.
51. Leleu X, Hunter ZR, Xu L, Roccaro AM, Moreau AS, Santos DD, et al. Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom macroglobulinemia. Br J Haematol. 2009; 145(1):59-63.
52. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009;459(7247):717-21.
53. Novak U, Rinaldi A, Kwee I, Nandula SV, Rancoita PM, Compagno M, et al. The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood. 2009;113(20):4918-21.
54. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, et al. Promiscuous mutations activate the noncanonical NFkappaB pathway in multiple myeloma. Cancer Cell. 2007;12(2):131-44.
55. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007;12(2):115-30.
56. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2002;99(24):15524-9.
57. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA. 2005;102 (39):13944-9.
58. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88(3):323-31.
59. Hunter Z, Xu L, Zhou Y, Yang G, Liu X, Cao Y, et al. Whole-Genome sequencing results from 30 patients with Waldenstrom's macroglobulinemia. Blood (ASH Annual Meeting Abstracts). 2011;118:Abstract 434.
60. Xu L, Sohani AR, Arcaini L, Hunter Z, Yang G, Zhou Y, et al. A somatic variant in MYD88 (L265P) revealed by whole genome sequencing differentiates lymphoplasmacytic lymphoma from marginal zone lymphomas. Blood (ASH Annual Meeting Abstracts). 2011;118: Abstract 261.
61. Jeong E, Lee JY. Intrinsic and extrinsic regulation of innate immune receptors. Yonsei Med J. 2011;52(3):379-92.
62. Zhu J, Mohan C. Toll-like receptor signaling pathways--therapeutic opportunities. Mediators Inflamm. 2010;2010:781235.
63. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470(7332):115-9.
64. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281-97.
65. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5(7):522-31.
66. Gangaraju VK, Lin H. MicroRNAs: key regulators of stem cells. Nat Rev Mol Cell Biol. 2009;10(2):116-25.
67. Hodge LS, Elsawa SF, Grote DM, Price Troska TL, Asmann YW, Fonseca R, et al. MicroRNA expression in tumor cells from Waldenstrom's macroglobulinemia reflects both their normal and malignant cell counterparts. Blood Cancer Journal. 2011;1.
68. Roccaro AM, Sacco A, Chen C, Runnels J, Leleu X, Azab F, et al. microRNA expression in the biology, prognosis, and therapy of Waldenstrom macroglobulinemia. Blood. 2009;113(18):4391-402.
69. Sacco A, Issa GC, Zhang Y, Liu Y, Maiso P, Ghobrial IM, et al. Epigenetic modifications as key regulators of Waldenstrom's macroglobulinemia biology. J Hematol Oncol. 2010;3:38.
70. Roccaro AM, Sacco A, Jia X, Azab AK, Maiso P, Ngo HT, et al. microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia. Blood. 2010;116(9):1506-14.
71. Chng WJ, Schop RF, Price-Troska T, Ghobrial I, Kay N, Jelinek DF, et al. Geneexpression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood. 2006;108(8):2755-63.
72. Gutierrez NC, Ocio EM, de Las Rivas J, Maiso P, Delgado M, Ferminan E, et al. Gene expression profiling of B lymphocytes and plasma cells from Waldenstrom's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia. 2007;21(3):541-9.
73. Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer. 2005;41(16):2502-12.
74. Hodge LS, Ansell SM. Jak/Stat pathway in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011;11 (1):112-4.
75. Elsawa SF, Novak AJ, Ziesmer SC, Almada LL, Hodge LS, Grote DM, et al. Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity. Blood. 2011;118(20):5540-9.
76. Hatjiharissi E, Ngo H, Leontovich AA, Leleu X, Timm M, Melhem M, et al. Proteomic analysis of Waldenstrom macro-globulinemia. Cancer Res. 2007;67(8): 3777-84.
77. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489-501.
78. Leleu X, Jia X, Runnels J, Ngo HT, Moreau AS, Farag M, et al. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood. 2007;110(13): 4417-26.
79. Yoeli-Lerner M, Toker A. Akt/PKB signaling in cancer: a function in cell motility and invasion. Cell Cycle. 2006;5(6):603-5.
80. Brader S, Eccles SA. Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. Tumori. 2004;90(1):2-8.
81. Sacco A, Roccaro A, Ghobrial IM. Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's macroglobulinemia. Oncotarget. 2010;1(7):578-82.
82. Guertin DA, Sabatini DM. The pharmacology of mTOR inhibition. Sci Signal. 2009; 2(67):pe24.
83. Ghobrial IM, Gertz M, Laplant B, Camoriano J, Hayman S, Lacy M, et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010;28 (8):1408-14.
84. Harir N, Pecquet C, Kerenyi M, Sonneck K, Kovacic B, Nyga R, et al. Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias. Blood. 2007;109(4):1678-86.
85. Ward AC, Touw I, Yoshimura A. The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood. 2000;95(1):19-29.
86. Ngo HT, Leleu X, Lee J, Jia X, Melhem M, Runnels J, et al. SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia. Blood. 2008;112(1):150-8.
87. Tsingotjidou AS, Emmanouilides CE, Siotou E, Poutahidis T, Xagorari A, Loukopoulos P, et al. Establishment of an animal model for Waldenstrom's macroglobulinemia. Exp Hematol. 2009;37 (4):469-76.
88. Tassone P, Neri P, Kutok JL, Tournilhac O, Santos DD, Hatjiharissi E, et al. A SCID-hu in vivo model of human Waldenstrom macroglobulinemia. Blood. 2005;106(4): 1341-5.
89. Tassone P, Neri P, Burger R, Savino R, Shammas M, Catley L, et al. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Clin Cancer Res. 2005;11(11): 4251-8.